The Indian economy is heading for interesting times. With the government trying to push key legislation like GST -- possibly on Aug 3 -- the future of the Indian economy is a topic on which a lot of consideration is presently being given. A recent World Bank report titled 'India Development Update-June 2016' sheds light on some of the pertinent aspects of the Indian economy.
Below is the views on Advanced Enzymes IPO Results By Ajay Saraf, Executive Director, (ICICI Securities Ltd)
Advanced Enzyme is a very exciting and unique story with high entry barriers. The fact that the company has been able to maintain its dominant position in the enzyme industry with consistent healthy operating margins has attracted hi
On the 25th anniversary of India's economic reforms, a general consensus seems to have emerged within the country and without that the next phase reforms must address what has so far eluded agreement among the principal stakeholders: land and labour. Make in India will not happen if these two main factors of production remain entangled in political one-upmanship.
The government ha
In a remote hamlet of Sikkim, a young man has a new toilet built by his house. He no longer escorts his wife and children before sunrise to the bushes in the fields, standing guard to shoo away wayside dogs and local pests. "I don't feel like an animal any more," he says.
In India, more than seven in 10 rural people have no access to toilets. Of the one billion people in
Expectations of political consensus on a major economic legislation, combined with above average monsoon rains and continued influx of foreign funds are expected to support the Indian rupee in the upcoming week.
"Strong FII (Foreign Institutional Investor) inflows, robust momentum in domestic equity markets, strong domestic macro theme supported by good monsoon and GST (Goods and
Below is the views on ICICI Bank Ltd 1QFY2017 Results By Mr. Siddharth Purohit (Sr. Equity Research Analyst- Banking, Angel Broking Pvt Ltd )
“ICICI Bank reported mixed set of results for the quarter, while the PAT number was on expected line, this has come on the back of higher other
Below is the views on Indoco Remedies Ltd 1QFY2017 Results By Ms. Sarabjit Kour Nangra (VP- Research Pharma, Angel Broking Pvt Ltd)
“For 1QFY2017, the company posted sales of INR 253cr V/s INR 220cr expected V/s INR 216cr in 1QFY2016, a YoY growth of 17.0%. The formulations (INR 234.5cr), a YoY growth of 14.8% YoY, while API (INR 175.
Below is the views on GlaxoSmithKline Pharmaceuticals Ltd 1QFY2017 Results By Ms. Sarabjit Kour Nangra (VP- Research Pharma, Angel Broking Pvt Ltd)
“For 1QFY2017, GlaxoSmithKline posted sales of INR 685cr V/s INR 700cr expected V/s INR 622cr in 1QFY2016, a YoY growth of 10.2%. The sales growth has been impacted on back of the pr